CD19 and diffuse large B-cell lymphoma: CD19 chimeric antigen receptor (CAR) T-cell therapies, such as Axicabtagene Ciloleucel, Lisocabtagene maraleucel, and tisagelecleucel, have shown sustained remission and manageable toxicity profiles in patients with relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), when used as second- or third-line strategies [1–5].